The Inflation Reduction Act’s Medicare drug price negotiation program may provide disincentives for the development of biosimilar development, James D. Chambers, Ph.D., a profes ...

Journavx revenue rose 71% QoQ and >4× YoY, supported by rapidly expanding utilization across hospital and retail channels, reaching nearly 900,000 prescriptions in 1H2026. Payer coverage broadened ...

Chambers, Ph.D., from Tufts Medical Center, discusses how biosimilars have improved access to biologics, but more work needs to be done for patients to see cost reductions. Biosimilars will continue ...

A randomized, open-label comparison in 31 children (mostly cerebral palsy) evaluated VR plus nitrous oxide versus standard distraction approaches during botulinum toxin injections. Pain scores ...

In this webinar, Tom Kraus, J.D., and Shawn Gremminger, M.P.P., debated the merits of the 340B Drug Pricing Program that allows many hospitals to buy outpatient drugs at discounted prices. Kraus, J.D.

Yesafili enters a growing U.S. aflibercept biosimilar class as the second launch after Amgen’s Pavblu, intensifying competition in high-volume retinal anti-VEGF indications. Interchangeable ...

Regulatory momentum, including CAA 2026, is accelerating full rebate pass-throughs, expanded fiduciary duties, and enhanced disclosures to plans and self-insured employers, with many provisions ...

Managed Healthcare Executive and the Pharmacy Benefit Management Institute (PBMI) are recognizing outstanding professionals in pharmacy benefits with the PBMI Innovators award. We are celebrating ...